bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.
Association of CD44-/CD24- Breast Cancer Cells with Late Stage Tumor
Recurrence
Xinbo Qiao1#, Yixiao Zhang2#, Lisha Sun1#, Qingtian Ma1#, Jie Yang3, Liping Ai4, Jinqi
Xue1, Guanglei Chen1, Hao Zhang5, Ce Ji6, Xi Gu1, Haixin Lei7, Yongliang Yang8 and
Caigang Liu1*.
1. Department of Oncology, Shengjing Hospital, China Medical University, Shenyang 110004, China. 2. Shengjing Hospital of China Medical University, Shenyang, 110004, China. 3. Tongji Medical College of HUST, Wuhan, 430030, China. 4. Department of Clinical Oncology, Xijing Hospital, Fourth Military Medical University, Xi’an 710032, China. 5. Department of Breast Surgery, Liaoning Cancer Hospital and Institute, Cancer Hospital of China Medical University, Shenyang, 110042, China. 6. Department of General Surgery, Shengjing Hospital, China Medical University, Shenyang 110004, China. 7. Institute of Cancer Stem Cell, Cancer Center, Dalian Medical University, Dalian, China. 8. Center for Molecular Medicine, School of Life Science and Biotechnology, Dalian University of Technology, Dalian, 116024, China. # Contributed equally
* Corresponding author
Keywords: Cancer stem cell, Late stage recurrence, Convertion, RHBDL2
Corresponding Author:
Dr. Caigang Liu, Department of Oncology, Shengjing Hospital, China Medical University,
Shenyang 110004, China.
Email: [email protected], Tel.: 86-18940254967 , Fax: 024-31939077
1 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.
Abstract
Tumor metastasis remains the main cause of breast cancer-related deaths, especially the later
breast cancer distant metastasis. This study assessed CD44-/CD24- tumor cells in 576 tissue
specimens for associations with clinicopathological features and metastasis and then
investigated the underlying molecular events. The data showed that level of CD44-/CD24-
cells was associated with later postoperative distant tumor metastasis. Furthermore, CD44-
/CD24- triple negative cells could spontaneously convert into CD44+/CD24- cancer stem cells
(CSCs) with properties similar to CD44+/CD24- CSCs from parental MDA-MB-231 cells in
terms of gene expression, tumor cell xenograft formation, and lung metastasis in vitro and in
vivo. Single-cell RNA sequencing identified RHBDL2 as a regulator that enhanced
spontaneous CD44+/CD24- CSC conversion, whereas knockdown of RHBDL2 expression
inhibited YAP/NF-κB signaling and blocked spontaneous CD44-/CD24- cell conversion to
CSCs. These data suggested that the level of CD44-/CD24- tumor cells could predict breast
cancer prognosis, metastasis, and response to adjuvant therapy.
2 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.
Introduction
Breast cancer is the most prevalent malignancy in women, and its incidence is increasing
worldwide, especially in developed countries (Bianchini et al., 2016; Siegel et al., 2020).
Different treatment strategies, such as surgical resection, hormone therapy, targeted therapy,
radiation therapy, and chemotherapy, have greatly improved the survival of breast cancer
patients (Bray et al., 2018; Burstein et al., 2014; Early Breast Cancer Trialists'
Collaborative, 2015; Khan et al., 2012; Saini et al., 2012). However, as such advancements
prolong patients’ survival, they also lead to an unfortunate and considerable number of
patients facing the risk in developing later breast cancer metastasis, even 20–40 years after
breast cancer diagnosis (Sharma, 2018). Notably, breast cancer metastasis occurring 5–8
years after initial surgical resection has become a significant cause of treatment relapse,
tumor progression, and poor survival of patients (Nishimura et al., 2013); thus, further
research on the underlying molecular mechanisms and gene alterations could help us to
identify novel biomarkers and treatment strategies to effectively control breast cancer
metastasis and progression. To date, clinical strategies for breast cancer treatment remain
suboptimal. Currently, the best option available is continuous tamoxifen treatment for 10
years, which has been shown to reduce cancer recurrence and mortality of patients; however,
a significant proportion of patients may be overtreated (Bianchini et al., 2016; O'Conor et al.,
2018). In this regard, we also urgently need to discover novel biomarkers to predict treatment
effectiveness and to improve treatment success and prognosis among breast cancer patients.
Indeed, tumor metastasis is a multistep process, involving tumor cell escape from the
primary site, migration into neighboring tissues, extravasation, survival, and colonization, all
leading to the formation of new tumor lesions at a secondary site (Drabsch and ten Dijke,
2011; Klein, 2008; Scott et al., 2012; Syn et al., 2016). The rate-limiting step of cancer
metastasis is tumor growth at the secondary site, because the tumor lesion initially lacks
3 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.
sufficient vasculature to provide nutrients for cancer cell growth. Thus, the newly arrived
tumor cells may grow to a certain size in the new and harsh microenvironment and then
experience growth arrest in that organ. However, once they regain their proliferative ability,
late metastasis will occur (Langley and Fidler, 2007). Molecularly, CD44+/CD24- tumor
cells from the breast primary tumor lesion are associated with distance metastasis (Abraham
et al., 2005), and these cells display increased motility and invasiveness (Liu et al., 2010)
similar to chemoresistant cancer stem cells (CSCs) (Velasco-Velazquez et al., 2011). Previous
studies have shown that CD44+/CD24- breast CSCs might be a dominant factor in relapse of
triple negative breast cancer (TNBC), due to their possession of potent self-renewal and
differentiation capacities to differentiate into mature CD44-/CD24-, CD44+/CD24+, and
CD44-/CD24+ cancer cells (Geng et al., 2014; Wang et al., 2014). Indeed, injection of up to
1000 breast CSCs was able to generate a solid tumor mass in immunocompromised mice
(Chaffer et al., 2011; Iliopoulos et al., 2011). Thus, the number of breast CSCs in the
secondary site could affect the efficiency of early metastasis formation, and stem cells are
more prone to be resistant to chemotherapy (De Angelis et al., 2019). Moreover, previous
studies reported that non-CSCs, such as CD44-/CD24- TNBC cells, are able to spontaneously
convert into CSCs to renew the CSC pool, resulting in chemoresistance(Gruber et al., 2016;
Kim et al., 2015; Ye et al., 2018). Thus, the dormant CD44-/CD24- tumor cells that have
previously been colonized in the metastatic site may be able to spontaneously convert to
CSCs to regain proliferative ability and drug resistance, resulting in later tumor metastasis.
Therefore, detection of CD44-/CD24- cells may be useful in the prediction of later breast
cancer metastasis.
In the present study, we aimed to identify the molecular mechanisms by which CD44-
/CD24- cell to CSC conversion promotes later breast cancer metastasis. We first performed a
retrospective analysis of CD44-/CD24- breast cancer cells in tissue specimens from patients
4 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.
enrolled from three academic medical centers to identify any associations between the
presence of these cells and postoperative tumor metastasis. We then performed in vitro and in
vivo experiments to confirm CD44-/CD24- cell conversion to CD44+/CD24- CSCs and then
assessed the properties of the converted CSCs in vitro and in vivo. This study provides novel
insight into the role of CD44-/CD24- tumor cells in later breast cancer metastasis and into the
potential use of CD44-/CD24- cells as a biomarker to predict survival and metastasis in breast
cancer patients or targeting of RHBDL2 as a novel therapeutic approach in the future.
Results
Association of high CD44-/CD24- tumor cell level with late breast cancer distant
metastasis
CD44+/CD24- breast CSCs were previously found to not have a significant impact on the
prognosis of breast cancer patients (Kaverina et al., 2017; Mylona et al., 2008). In the present
study, we performed a retrospective analysis of CD44+/CD24- cell levels in 576 patients
using immunofluorescence staining to examine their association with clinicopathological
factors. The patients were divided into a training set (n= 355) and testing set (n= 221) (Table
S1) for assessment of cell membrane proteins CD44 and CD24 (Fig. S1), leading to four
- + - - + types of breast cancer cells (CD44 /CD24-, CD44 /CD24 , CD44 /CD24 , and
CD44+/CD24+), as shown in Fig. S2A. The level of CD44-/CD24- cells was significantly
higher in breast cancer tissues of patients with postoperative tumor metastasis in the training
set (P<0.0001; Fig. 1A). The receiver-operating characteristic curve analysis showed a
decision threshold of 19.5% CD44-/CD24- cancer cells, and thus, we used this cut-off-point
to perform a subgroup analysis (the discrimination criteria are shown in Fig. 1B). In the
5 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.
training set of patients, the metastasis rate was 1.97-fold higher in patients with a high level
of CD44-/CD24- breast cancer cells (>19.5%) than in those with a low level of CD44-/CD24-
tumor cells (<19.5%). Similar data were obtained after analysis of the three breast cancer
subtypes (i.e., luminal: 63.1% vs. 32.58%; HER-2: 49.02% vs. 15%; TNBC: 56.96% vs.
20.28% for high vs. low CD44-/CD24- tumor cells; Fig. 1C). Our univariate analysis showed
that the CD44-/CD24- cancer cell subgroup, CSCs percentage, lymph node metastasis, N
stage, estrogen receptor and progesterone receptor status, and molecular subtype were all
predictors of DFS (Table S2).
Furthermore, the DFS of patients with a high CD44+/CD24- or CD44-/CD24- tumor cell
level was shorter than that of patients with a low frequency (Fig. 1E), which was also
observed in the three breast cancer subtypes (Fig. S2D and S3A). The kinetic curve pattern
analysis also showed that patients with a high CSC percentage had a high risk of developing
early tumor metastasis within the first 3 years after diagnosis (Fig. S3C). Some patients with
high CD44-/CD24- tumor cell levels also possessed a high CSC percentage and showed a
higher rate of postoperative metastasis. However, to exclude the effects of CSCs, we defined
patients with <2% CD44+/CD24- and > 19.5% CD44-/CD24- tumor cells as the C1 group, and
our data revealed that these C1 patients had a high risk of developing later tumor metastasis
after 5–7 years (Fig. 1D).
Level of CD44-/CD24- breast cancer cells predicts success of postoperative TNBC
treatment
We then confirmed our data using the testing set of patients and found that the metastasis
rate was higher in patients with a high CD44-/CD24- tumor cell level among all breast cancer
subtypes (luminal: 63.1% vs. 32.58%; HER-2: 49.02% vs. 15%; TNBC: 56.96% vs. 20.28%
for high vs. low CD44-/CD24- cells; Fig. 2A). The DFS and OS of patients with a high CD44-
6 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.
/CD24- percentage were shorter than those of patients with a low CD44-/CD24- cell
percentage (Fig. 2CD). Moreover, the DFS and OS of patients stratified by breast cancer
subtype also were shorter with a high CD44-/CD24- percentage vs. low CD44-/CD24-
percentage (Figure S5A,B). The kinetic curve pattern analysis also confirmed that C1 patients
had a later metastasis peak than all other patients (Fig. 2B).
Furthermore, we analyzed the predictive value of the CD44-/CD24- cell percentage for
response to treatment. In the training set of patients, cases with a high CD44-/CD24- cell level
after chemotherapy had a higher risk of developing tumor metastasis 4 years after initial
diagnosis and treatment than did cases with a low CD44-/CD24- cell percentage (Fig. S3B).
Moreover, a low CSC percentage led to different risks for developing tumor metastasis 5
years after diagnosis and adjuvant chemotherapy between the C1 and C0 patients (Fig. S3D).
TNBC patients with high and low CD44-/CD24- cell levels also had different risks of
metastasis 4 years after diagnosis and chemotherapy, indicating that chemotherapy per se did
not effectively inhibit tumor progression (metastasis) (Fig. 2F). In this regard, detection of
CD44-/CD24- cells in tumor tissues could be a valuable predictor of chemotherapy response.
The data from our testing group of patients confirmed these results (Fig. 2E and S4CD). In
addition, patients with luminal breast cancer treated with endocrine therapy also showed
significantly different prognoses after stratification by percentage of CD44-/CD24- cells in
both the training and testing groups of patients (Fig. 1FG).
Spontaneous conversion of CD44-/CD24- TNBC cells into CD44+/CD24- CSCs in vitro
Previous studies showed that non-CSCs are able to spontaneously convert into CSCs to
renew the CSC pool, although it remained unclear whether the stem cells derived from the
non-CSCs have the same biological behavior as the original stem cells (Najafi et al., 2019).
In the present study, we first designed the experiments illustrated in Fig. 3A to characterize
7 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.
the percentages of different cell subtypes among MDA-MB-231 cells using cell culture and
flow cytometric cell sorting of parental MDA-MB-468 cells. We found that the percentage of
CD44+/CD24- CSCs was 18.7% and that of CD44-/CD24- CSCs was 73.4%. Next, we sorted
the CD44-/CD24- cells and continued to culture them in the stem cell (SC) and normal
complete L15 medium for 7 days. We found that 28.3% of CD44-/CD24- cells were able to
spontaneously convert into CD44+/CD24- CSCs, which was higher than the 24.7% observed
when the cells were cultured in the normal complete L15 medium (Fig. 3B). Similar results
were observed in the parental MDA-MB-468 cells (Fig. S5). Moreover, the percentage of
CD44+/CD24- CSCs was even higher after 21 days in culture than after 7 days in culture (Fig.
3C), suggesting that CD44-/CD24- TNBC cells were able to spontaneously convert into
CD44+/CD24- CSCs.
Similar properties of newly converted CSCs from CD44-/CD24- TNBC cells to those
directly derived from TNBC cells in vitro
The clinical usefulness of CD44-/CD24- cells in breast cancer lesions is obvious; thus, we
explored the underlying mechanism by assessing whether these newly converted
CD44+/CD24- CSCs from CD44-/CD24- MDA-MB-231 cells possessed comparable stemness
properties to CSCs derived directly from parental MDA-MB-231 cells. We assessed changes
in mammosphere formation, tumor cell differentiation ability, and expression of CSC
biomarkers in the CSCs from these two sources in vitro as well as their tumorigenicity in
vivo. We found that both CSC types, from the parental cell line and from their conversion
from CD44-/CD24- MDA-MB-231 cells, formed mammospheres similar in size and number
(Fig. 4A) and displayed similar proliferative capacity (Fig. 4B). Culture of both types of
CSCs for 7 days promoted their differentiation into different MDA-MB-231 cell subtypes at
similar frequencies (Fig. 4CE). Western blot analysis showed that the expression of OCT4,
8 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.
SOX2, NANOG, NESTIN, and ABCB1 proteins was also comparable between these two
types of CSCs (Fig. 4D). Thus, these results indicated that the newly converted CSCs from
CD44-/CD24- breast cancer cells and the CSCs derived directly from parental MDA-MB-231
cells exhibited comparable levels of tumor cell proliferation, differentiation, mammosphere
formation, and stemness properties.
Similar tumorigenesis and distant metastasis properties of CSCs derived from
conversion of CD44-/CD24- TNBC cells and directly from parental TNBC MDA-MB-
231 cells in vivo
Next, we assessed whether the two types of CSCs functioned similarly in vivo. We
inoculated BALB/c nude mice with equal numbers of the two types of CSCs, and 21 days
later, we observed xenograft tumors of similar size and weight (Fig. 5A). Our flow
cytometric analysis of these xenograft tumor cells showed similar frequencies of different
breast cancer cell subtypes (Fig. 5B). Furthermore, injection of equal numbers of the two
types of CSCs into the left ventricle of NOD/SCID mice also resulted in a similar incidence
of tumor cell lung metastasis and metastasized tumors of similar size and weight (Fig. 5C).
H&E staining of the metastasized tumors showed they had similar histology (Fig. 5C). Thus,
the CSCs obtained from CD44-/CD24- TNBC cells had similar abilities of tumorigenesis and
metastasis in vivo compared with those obtained directly from parental TNBC cells.
Involvement of RHBDL2 in spontaneous CD44-/CD24- tumor cell conversion to
CD44+/CD24- CSCs
To further understand the molecular mechanisms underlying the CD44-/CD24- cell
conversion of TNBC cells, we first sorted CD44-/CD24- cells from parental MDA-MB-231
cells and transfected them with an OCT4-EGFP plasmid (indicative of stem-like cells; Fig.
9 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.
6A). We then isolated and cultured the single cells in complete L15 medium and performed
RNA-seq to identify DEGs at 24 or 72 h after gene transfection. Our analysis revealed 11
DEGs associated with tumor cell differentiation and dedifferentiation after 24 h in cell culture
(including RHBDL2, DSCC1, ZNF710, ATP8B3, and others; Fig. 6B and Fig. S6A). Our
GO and KEGG analyses revealed that the reverse differentiation predominantly affected the
expression levels of proteins involved in cell organelle formation, metabolism, signal
transduction, and transcriptional regulation (Fig. S6BC). Furthermore, we performed Kaplan-
Meier curve analysis and log-rank test to analyze associations between select DEGs and
breast cancer prognosis using The Cancer Genome Atlas (TCGA) data (Fig. 6C). This
analysis showed that high expression of HIST1H4H, ZNF710, RHBDL2, DSCC1, ARL6IP1,
and PPME1 mRNAs was associated with a poor prognosis in breast cancer patients, whereas
low expression of SLC35F5, G2E3, ATP8B3, and MED22 mRNAs also was associated with
a poor prognosis of breast cancer patients. Furthermore, we cultured breast cancer cells for 7
days and then divided them into CD44+/CD24- breast cancer stem cells, CD44-/CD24- double
negative cells, and dedifferentiated stem cells for detection of the expression levels of
different mRNAs. We found that RHBDL2 expression was high during tumor cell
dedifferentiation, suggesting that RHBDL2 may play a key role in the process of breast
cancer cell dedifferentiation.
Downregulated RHBDL2 expression inhibits YAP/nuclear factor (NF)-κB/interleukin
(IL)-6 signaling and spontaneous CD44-/CD24- cell conversion to CD44+/CD24- CSCs
To further explore how RHBDL2 and the related gene signaling are involved in the
control of spontaneous CD44-/CD24- cell conversion to CD44+/CD24- CSCs, we first assayed
the levels of total YAP1 and phosphorylated YAP1 in MDA-MB-231 cells (Fig. 7A) and
found that phosphorylated YAP1 was increased with RHBDL2 silencing. Previous studies
10 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.
revealed that the YAP signaling is able to suppress USP31 expression, a potent inhibitor of
NF-κB signaling in cells (17, 20). We thus further examined USP31 expression and NF-κB
phosphorylation in CD44-/CD24- cells sorted from both the negative control (NC) and
RHBDL2-silenced MDA-MB-231 cells. Our results showed that USP31 expression was
significantly higher in CD44-/CD24- RHBDL2-silenced cells than in NC MDA-MB-231
cells, whereas the level of phosphorylated NF-κB was significantly lower in CD44-/CD24-
RHBDL2-silenced cells than in CD44-/CD24- cells from negative control siRNA-transfected
MDA-MB-231 cells (Fig. 7B). Furthermore, we investigated changes in the YAP1
distribution in the nucleus and cytoplasm of CD44-/CD24- RHBDL2-silenced cells vs. CD44-
/CD24- cells from negative control siRNA-transfected MDA-MB-231 cells. Our data showed
that both the nuclear and cytoplasmic levels of YAP1 protein were lower in RHBDL2-
silenced cells than in negative control siRNA-transfected cells (Fig. 7C).
We next selected the CD44-/CD24- cells using flow cytometric sorting and transfected
them with an RHBDL2-specific siRNA. After 7 days, the cell content was observed by flow
cytometric analysis. The results showed that the ratio of CD44+/CD24- CSCs dedifferentiated
from NC cells was 6.5% and the ratio of siRHBDL2 cells converted to stem cells was 0.7%
(Fig. 7D). Similar results were observed for parental MDA-MB-468 cells (Fig. 7E), with
rates of CSC production of 5.5% (NC) and 0.5% (siRHBDL2). Then, we transfected CD44-
/CD24- MDA-MB-231 cells with negative control or RHBDL2-specific siRNA for 48 h (the
transfection efficiency reached 62% and the knockdown of RHBDL2 expression was
significant; P<0.01). After 7 days in culture, RHBDL2 silencing in CD44-/CD24- MDA-MB-
231 cells dramatically reduced the level of CD44+/CD24- CSCs (P<0.01; Fig. 7F), and the
number and size of the formed mammospheres were significantly less compared with those
of CD44-/CD24- cells from negative control-transfected MDA-MB-231 cells (P<0.05 and
P<0.01, respectively; Fig. 7F). Specifically, RHBDL2 downregulated YAP1 expression to
11 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.
increase USP31 and decrease NF-κB signaling, and in turn, induce spontaneous conversion
of CD44-/CD24- TNBC cells into CD44+/CD24- CSCs, whereas knockdown of RHBDL2
expression had the opposite effects in TNBC cells (Fig. 7G).
Discussion
Our current study revealed that (a) CD44-/CD24- TNBC MDA-MB-231 cells were able
to spontaneously convert to CD44+/CD24- CSCs, which is consistent with previous studies
showing that non-tumor and neoplastic non-stem cells and CD44-/CD24- breast cancer cells
can spontaneously convert into CSCs in vitro (Italiano and Shivdasani, 2003; Zoppino et al.,
2010); (b) CD44+/CD24- CSCs converted from CD44-/CD24- cells had similar biological
properties compared to CSCs isolated from parental MDA-MB-231 cells in terms of
proliferation capacity, gene expression, tumor cell xenograft formation, and lung metastasis
in vitro and in vivo; (c) the percentage of CD44-/CD24- cells was associated with later
postoperative distant tumor metastasis; (d) the percentages of CD44-/CD24- and
CD44+/CD24- cells, tumor N stage, and molecular subtypes were all predictors of DFS for
breast cancer patients; and (e) mechanistically, knockdown of RHBDL2 expression inhibited
YAP/NF-κB/IL-6 signaling and blocked the spontaneous CD44-/CD24- cell conversion to
CD44+/CD24- CSCs. In conclusion, this study demonstrated that the CD44-/CD24- cell
population in breast cancer lesions was associated with breast cancer prognosis and distant
metastasis as well as the success of adjuvant therapy. Further research is needed to
investigate the role of RHBDL2 in breast cancer development and tumor cell
dedifferentiation as a potential novel target in control of breast cancer progression.
The dedifferentiation (conversion) of non-CSC tumor cells into CSCs also occurs in
other types of human cancers, such as glioblastoma and intestinal stroma melanoma, and
contributes to intra- and inter-tumor heterogeneity (Stepanova et al., 2003; Tzimas et al.,
12 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.
2006; Wei et al., 2019). Although the underlying molecular mechanisms remain to be
defined, CSC plasticity and heterogeneity could induce tumor progression and resistance to
therapy (Das et al., 2020; Kilmister et al., 2020; Martin-Castillo et al., 2013; Thankamony et
al., 2020). For example, intratumoral heterogeneity is a major ongoing challenge for effective
cancer therapy, while CSCs are responsible for intratumoral heterogeneity, therapeutic
resistance, and metastasis, which may be because cancer cells exhibit a high level of
plasticity and an ability to dynamically switch between CSC and non-CSC states or among
different subsets of CSCs (Thankamony et al., 2020). Another previous study showed that the
differentiated non-CSCs are able to revert to trastuzumab-refractory, CS-like cells by
activation of the tumor cell epithelial-to-mesenchymal transition process (Martin-Castillo et
al., 2013). Conversion of non-CSCs to CSCs due to changes in tumor microenvironment and
epigenetics could result in tumor progression and therapy failure (Das et al., 2020). Our
current study further confirmed that the CD44-/CD24- TNBC MDA-MB-231 cells
spontaneously converted to CD44+/CD24- CSCs and such CSCs possessed similar biological
properties to CSCs isolated from parental MDA-MB-231 cells in terms of proliferation
capacity, gene expression, tumor cell xenograft formation, and lung metastasis in vitro and in
vivo. Indeed, the breast cancer MDA-MB-231 cell line was isolated and established from a
pleural effusion of a 51-year-old white female in 1973 by Dr. R. Calleau of the University of
Texas M.D. Anderson Cancer Center and does not express estrogen and progesterone
receptors or HER2; thus, the MDA-MB-231 line is a TNBC cell line (Cailleau et al., 1974)
(https://en.wikipedia.org/wiki/List_of_breast_cancer_cell_lines#MDA-MB-231) with
naturally high CD44 expression and low CD24 expression (Murohashi et al., 2010).
However, the factors that regulate this conversion of CD44-/CD24- TNBC non-CSCs to
CD44+/CD24- CSCs remained incompletely understood, and our current study provides some
insightful information, i.e., knockdown of RHBDL2 expression inhibited YAP/NF-κB/IL6
13 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.
signaling and blocked the spontaneous CD44-/CD24- cell conversion to CD44+/CD24- CSCs.
However, but further studies are needed to fully understand how RHBDL2 and the
downstream YAP/NF-κB/IL-6 signaling mediate the regulation of this conversion.
Furthermore, our multicenter retrospective analysis of CD44-/CD24- cancer cells in
breast cancer tissue specimens showed that the CD44-/CD24- cancer cell population was
associated with postoperative breast cancer metastasis. Our multivariate Cox regression
analysis revealed that percentages of CD44-/CD24- and CD44+/CD24- cells, tumor N stage,
and molecular subtypes were all predictors of DFS for breast cancer patients. The percentage
of CD44-/CD24- cancer cells could be a better predictor of later breast cancer metastasis (up
to 12 years after initial breast cancer diagnosis) than of early metastasis (within 5 years). Our
C1 subgroup of patients had a higher risk of later metastasis at 5–7 years after surgery. The
ROC curve analysis showed that the percentage of CD44-/CD24- cells could predict later
metastasis in cases with a low CSC percentage. These results further suggest that CD44-
/CD24- cells could be able to spontaneously convert into CSCs and cause distant metastasis,
although another theory of the clonal evolution also indicates that successive mutations
accumulating in a given cell line may lead to clonal outgrowth in response to
microenvironmental selection pressures (Meacham and Morrison, 2013).
In addition, our RNA-seq analysis identified several DEGs during the dynamic process
of CD44-/CD24- TNBC cell conversion into CSCs, i.e., expression of RHBDL2, YAP1, and
other genes were significantly increased. Consistently, YAP/USP31/NF-κB signaling was
activated in CD44-/CD24- MDA-MB-231 cells, which is consistent with previous research
showing that YAP1-mediated suppression of USP31 enhances NF-κB activity to promote
sarcomagenesis (Kemeny and Fisher, 2018; Mehta et al., 2018). YAP1 can enhance CSC
stemness in several types of human cancers, and aberrant YAP1 activation was associated
with a low level of TNBC differentiation and poor survival of breast cancer patients (Bora-
14 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.
Singhal et al., 2015; Hansen et al., 2015). Our current data could indicate that upregulated
RHBDL2 during CD44-/CD24- TNBC cell conversion into CSCs could enhance YAP
expression to, in turn, inhibit USP31 and attenuate its inhibition of NF-κB signaling, leading
to the enhanced conversion of CD44-/CD24- TNBC cells into CSCs.
In summary, postoperative breast cancer metastasis, especially later metastasis (e.g., ≥5
years after diagnosis), is an important unresolved issue. Our current results showed that
patients with high CD44-/CD24- cell populations had a high risk of developing metastasis 5–7
years after diagnosis. Knockdown of RHBDL2 expression caused YAP1 reduction and
enhanced USP31/NF-κB signaling, leading to inhibition of the conversion of CD44-/CD24-
TNBC cells into CSCs. Furthermore, inhibition of the YAP1 signal could attenuate or even
reverse the dedifferentiation process of TNBC cells. These findings provide novel insight into
the molecular process of the dedifferentiation of non-CSCs into CSCs, which was been
reported in glioblastoma, intestinal stroma melanoma, and other cancers, leading to cancer
progression. Thus, our current findings suggest a novel postoperative therapeutic strategy for
TNBC. Future studies will investigate targeting of RHBDL2 to control breast cancer
resistance to chemotherapy.
Materials and Methods
Patients and tissue specimens
Paraffin-embedded cancer tissue samples were collected from 576 breast cancer patients who
underwent breast cancer surgery between June 2005 and April 2013 in China Medical
University Affiliated Hospital (Shenyang, Liaoning, China), Liaoning Cancer Hospital
(Shenyang, Liaoning, China), and Dalian Municipal Central Hospital Affiliated of Dalian
Medical University (Dalian, Liaoning, China). These patients were diagnosed with invasive
breast cancer histologically according to the World Health Organization (WHO) breast
15 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.
cancer classifications, 4th edition (Tan et al., 2015) and classified according to breast cancer
TNM staging(Li et al., 2012). The patients’ clinicopathological data and follow-up data were
collected from their medical records or via telephone interview. The inclusion criteria were:
(a) surgical treatment for breast cancer; (b) complete information regarding
clinicopathological characteristics; and (c) complete follow-up data. Disease-free survival
(DFS) was defined as the time from the date of surgery to the date of distant metastasis, while
overall survival (OS) was defined as the time from the date of surgery to the date of death.
This study was approved by the ethics committee of all three hospital review boards, and
each participant signed an informed consent form before being included in this study.
Immunofluorescence staining
Paraffin-embedded cancer tissue blocks from 576 breast cancer patients were collected and
used to construct a tissue microarray (Edge and Compton, 2010) . The levels of CD44 and
CD24 expression were assayed by using a double immunofluorescence staining in these
tissue microarray sections. Briefly, 4-µm-thick sections of the tissue microarray were
prepared, deparaffinized, rehydrated, and subjected to the antigen retrieval as described
previously. Then the sections were incubated in 10% fetal bovine serum (FBS, Cellmax,
Lanzhou, China) at room temperature for 1 h before incubation with a mouse anti-human
CD44 monoclonal antibody (Cat. #3570; Cell Signaling Technology, Danvers, MA, USA)
and a rabbit anti-human CD24 antibody (Cat. #ab202073; Abcam, Cambridge, MA, USA) at
4ºC overnight. On the next day, the sections were washed with phosphate-buffered saline
(PBS) briefly three times and further incubated with the Alexa Fluor 647-labeled rabbit goat
anti-mouse IgG and Alexa Fluor 488-labeled goat anti-rabbit IgG, followed by nuclear
staining with 4',6-diamidino-2-phenylindole (DAPI). The fluorescence signals of the
immunostained tissue sections were observed and recorded under a fluorescence microscope
16 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.
(Nikon, Tokyo, Japan). The percentages of CD44+/CD24- CSCs and CD44-/CD24- cells were
calculated among a total of 2000 tumor cells from at least three sections in a blinded manner.
The fluorescence images were obtained using a Nikon E800 upright microscope with NIS-
Elements F3.0 (Nikon) and analyzed using ImageJ software (National Institute of Heath,
Bethesda, MD, USA).
Cell lines and culture
Human TNBC cell lines MDA-MB-231 and MDA-MB-468 were obtained from American
Type Culture Collection (ATCC; Manassas, VA, USA) and maintained in Leibovitz’s L15
medium (Thermo Fisher, Carlsbad, CA, USA) supplemented with 10% FBS, 100 U/ml
penicillin, and 100 µg/ml streptomycin (as the complete L15 medium) in a humidified
incubator without addition of CO2 at 37ºC.
The sorted CD44-/CD24- cells (see below) were then cultured in the complete L15
medium or the stem cell (SC) medium (10% human MammoCult Proliferation Supplements
in MammoCult Basal Medium, Stem Cell Technologies, San Diego, CA, USA) for 7 days.
The cells were then subjected to different assays (see below).
Flow cytometry
Parental MDA-MB-231 (wild-type, WT), RHBDL2-silenced MDA-MB-231, MDA-MB-
468/Ctrl, and MDA-MB-468/sh cells were grown and subjected to incubation with
fluorescein isothiocyanate (FITC)-conjugated anti-CD24 (Cat. #311104; BioLegend, San
Diego, CA, USA) and PE-conjugated anti-CD44 (Cat. #338808; BioLegend) antibodies.
Cells stained with an isotype control, FITC-anti-CD24 or PE-anti-CD44 alone served as
negative controls. Then, the percentages of CD44-/CD24-, CD44-/CD24+, CD44+/CD24+, and
17 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.
CD44+/CD24- cells were analyzed by using a FACSAria III flow cytometer (BD Biosciences,
San Jose, CA, USA).
siRNA and cell transfection
The yes-associated protein (YAP)-specific siRNA (5'-CAGUGUUUCAUACUCAAAU-3'),
RHBDL2-specific siRNA (5'-CAUACUUGGAGAGAGAGCUAATT-3'), and negative
control siRNA (5'-UUCUCCGAACGUGUCACGUTT-3') were obtained from GenePharma
(Shanghai, China) and used to knockdown expression of the corresponding genes. In
particular, CD44-/CD24- MDA-MB-231 cells were cultured in 6-well plates overnight at a
density of 5 × 105 cells/well until they reached 70% confluency when they were transiently
transfected with the YAP-specific siRNA, RHBDL2-specific siRNA, or negative control
siRNA using Mission siRNA transfection reagents (Sigma-Aldrich, St. Louis, MO, USA) for
48 h. The efficacy of silencing for each specific gene was evaluated by using western blot
analysis.
Western blot analysis
Cells were lysed in radioimmunoprecipitation (RIPA) lysis buffer containing phenylmethane
sulfonyl fluoride (PMSF) and protease and phosphatase inhibitors. After centrifugation at
12000 rpm at 4°C for 20 min, the supernatants were collected, and the total protein
concentration was measured using a Pierce BCA Protein Assay Kit (Thermo-Fisher)
according to the manufacturer’s instructions. Next, these individual cell lysate samples (50
µg/lane) were separated by 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) gels and transferred onto polyvinylidene difluoride (PVDF) membranes
(Millipore, Billerica, MA, USA). For western blotting, the membranes were blocked in 5%
nonfat dry milk in Tris-based saline-Tween 20 (TBS-T) at room temperature for 1 h and then
18 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.
incubated overnight at 4°C with various primary antibodies (Supplementary Table 3).
Primary antibodies bound to the membranes were detected with horseradish peroxidase
(HRP)-conjugated secondary antibodies (1:10000 dilution; Cat. #ZDR-5306, ZDR-5307, or
ZSGB-BIO, Beijing, China), and the immunoblotting signal was visualized using enhanced
chemiluminescence reagents (Cat. #34076; Thermo-Fisher, Waltham, MA, USA) on
chemiluminescence instrument C300 (Azure, Dublin, CA, USA). The levels of individual
target proteins relative to the level of the glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) control were determined by densitometric analysis using ImageJ software.
Single-cell RNA sequencing (RNA-seq)
The OCT4 promoter–controlled enhanced green fluorescent protein (EGFP) expression
vector was constructed by cloning the human OCT4 promoter region (1–2012 bp) using
polymerase chain reaction (PCR) and inserted with a DNA fragment of EGFP cDNA into the
plasmid pGL3-basic at the Nhel and BglII sites to generate pGL3-OCT4-EGFP and
sequenced. Next, the CD44-/CD24- MDA-MB-231 cells were grown and sorted by flow
cytometry. The collected cells were grown and transfected with pGL3-OCT4-EGFP using
Lipofectamine 3000 (Invitrogen, Carlsbad, CA, USA) and transferred into QuAscount assay
plates for 1 or 3 days for capture of the single cells using a microraft (Teacon, Maennedorf,
Switzerland) according to the manufacturer’s instructions at 24, 72, and 120 h and subjected
to RNA-seq analysis to identify differentially expressed genes (DEGs).
The DEGs in the 24- and 72-h samples were identified by RNA-seq. In brief, total RNA
was isolated from individual single-cell samples, and their mRNA was enriched using the
oligo-dT microbeads and fragmented to 300–500 bp before being reversely transcribed into
cDNA. The cDNA samples were amplified by PCR to generate cDNA libraries, and the latter
were sequenced with an Illumina HiSeqTM (Illumina, San Diego, CA, USA). The high-quality
19 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.
reads were aligned to the mouse reference genome (GRCm38) using the Bowtie2 v2.4.2
(Baltimore, MD, USA), and the expression level of individual genes was normalized to the
fragments per kilobase of the exon model per million mapped reads from RNA-seq by
expectation maximization. DEGs were considered significant if the gene expression
difference changed >2-fold compared to the control and had an adjusted p-value of <0.05.
Bioinformatics analysis
The DEGs were further analyzed by gene ontology (GO) with the online tool AMIGO
(http://www.geneontology.org) and Database for Annotation, Visualization and Integrated
Discovery (DAVID) software. The enrichment degrees of differentially expressed proteins
(DEPs) and DEGs were analyzed using the Kyoto Encyclopedia of Genes and Genomes
(KEGG; http://www.genome.jp/kegg) annotations.
Nude mouse tumor cell xenograft and lung metastasis assays
The experimental protocol was approved by the Animal Research and Care Committee of
China Medical University (Shenyang, China) and followed the Guidelines of the Care and
Use of Laboratory Animals issued by the Chinese Council on Animal Research. Female
BALB/c nude mice (6 weeks old) were obtained from Human Silaikejingda Laboratory
Animals (Changsha, China) and housed in a specific pathogen-free facility with free access to
autoclaved food and water. CSCs from parental MDA-MB-231 and CD44-/CD24- converted
MDA-MB-231 cells were injected into individual BALB/c nude mice (2 × 103 cells/mouse).
Tumor growth and body weight were monitored until 21 days post-tumor cell inoculation. At
the end of the experiment, subcutaneous tumors were recovered and weighed. In addition,
some tumor cell xenografts were recovered from each group at 7 and 21 days after
inoculation and digested to prepare single-cell suspensions for staining with FITC-anti-CD24,
20 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.
PE-anti-CD44, or isotype controls for flow cytometric sorting of CD44+/CD24-, CD44-
/CD24-, CD44-/CD24+, and CD44+/CD24+ cells.
Moreover, an equal number (1 × 103 cells/mouse) of CSCs from CD44+/CD24- and
CD44-/CD24- converted MDA-MB-231 cells were injected into the tail vein of NOD/SCID
mice and grown for 21 days to assess their lung metastasis. Afterward, the mice were
sacrificed and the tumor cell lung metastasis was resected. The metastatic tissue was
processed for hematoxylin and eosin (H&E) staining and photographed (n=5–8 per group).
Additionally, tumor weight and sizes were measured in each group.
Statistical analysis
The data were expressed as the mean ± the standard deviation (SD), and the differences
between the groups were analyzed by chi-squared or Student’s t tests, as applicable. The
statistics of all biological experiments were based on more than three independent replicated
experiments. The DFS of each group of patients was estimated by the Kaplan-Meier curves
and analyzed using the log-rank test. All statistical analyses were performed using SPSS 23.0
(SPSS, Inc., Chicago, IL, USA). A p-value less than or equal to 0.05 was considered
statistically significant.
Conflicts of interest
The authors declare that there are no conflicts of interest in this work.
Acknowledgements
This work was supported by grants from The National Natural Science Foundation of China
(#81872159, #81572609, and #31601142) and the Major Project Construction Foundation of
China Medical University (#2017ZDZX05).
21 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.
Author contribution
Caigang Liu conceived and designed the experiments; Xinbo Qiao, Lisha Sun and Yixiao
Zhang prepared the manuscript; Qingtian Ma, Jie Yang and Liping Ai performed the
experiments; Jinqi, Guanglei Chen, Hao Zhang, Ce Ji, Xi Gu, Haixin Lei ,and Yongliang
Yang analyzed the data.
References
Abraham, BK, Fritz, P, McClellan, M, Hauptvogel, P, Athelogou, M, and Brauch, H. 2005.
Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical
outcome but may favor distant metastasis. Clin Cancer Res 11, 1154-1159. PMID:15709183.
Bianchini, G, Balko, JM, Mayer, IA, Sanders, ME, and Gianni, L. 2016. Triple-negative
breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol
13, 674-690. DOI: https://doi.org/10.1038/nrclinonc.2016.66, PMID:27184417.
Bora-Singhal, N, Nguyen, J, Schaal, C, Perumal, D, Singh, S, Coppola, D, and Chellappan, S.
2015. YAP1 Regulates OCT4 Activity and SOX2 Expression to Facilitate Self-Renewal and
Vascular Mimicry of Stem-Like Cells. Stem Cells 33, 1705-1718. DOI:
https://doi.org/10.1002/stem.1993, PMID:25754111.
Bray, F, Ferlay, J, Soerjomataram, I, Siegel, RL, Torre, LA, and Jemal, A. 2018. Global
cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin 68, 394-424. DOI:
https://doi.org/10.3322/caac.21492, PMID:30207593.
Burstein, HJ, Temin, S, Anderson, H, Buchholz, TA, Davidson, NE, Gelmon, KE, Giordano,
SH, Hudis, CA, Rowden, D, Solky, AJ, Stearns, V, Winer, EP, and Griggs, JJ. 2014.
Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer:
22 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.
american society of clinical oncology clinical practice guideline focused update. J Clin Oncol
32, 2255-2269. DOI: https://doi.org/10.1200/JCO.2013.54.2258, PMID:24868023.
Cailleau, R, Young, R, Olive, M, and Reeves, WJ, Jr. 1974. Breast tumor cell lines from
pleural effusions. J Natl Cancer Inst 53, 661-674. DOI: https://doi.org/10.1093/jnci/53.3.661,
PMID:4412247.
Chaffer, CL, Brueckmann, I, Scheel, C, Kaestli, AJ, Wiggins, PA, Rodrigues, LO, Brooks,
M, Reinhardt, F, Su, Y, Polyak, K, Arendt, LM, Kuperwasser, C, Bierie, B, and Weinberg,
RA. 2011. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like
state. Proc Natl Acad Sci U S A 108, 7950-7955. DOI:
https://doi.org/10.1073/pnas.1102454108, PMID:21498687.
Das, PK, Pillai, S, Rakib, MA, Khanam, JA, Gopalan, V, Lam, AKY, and Islam, F. 2020.
Plasticity of Cancer Stem Cell: Origin and Role in Disease Progression and Therapy
Resistance. Stem Cell Rev Rep 16, 397-412. DOI: https://doi.org/10.1007/s12015-019-09942-
y, PMID:31965409.
De Angelis, ML, Francescangeli, F, and Zeuner, A. 2019. Breast Cancer Stem Cells as
Drivers of Tumor Chemoresistance, Dormancy and Relapse: New Challenges and
Therapeutic Opportunities. Cancers (Basel) 11. DOI:
https://doi.org/10.3390/cancers11101569, PMID:31619007.
Drabsch, Y, and ten Dijke, P. 2011. TGF-beta signaling in breast cancer cell invasion and
bone metastasis. J Mammary Gland Biol Neoplasia 16, 97-108. DOI:
https://doi.org/10.1007/s10911-011-9217-1, PMID:21494783.
Early Breast Cancer Trialists' Collaborative, G. 2015. Aromatase inhibitors versus tamoxifen
in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 386, 1341-
1352. DOI: https://doi.org/10.1016/S0140-6736(15)61074-1, PMID:26211827.
23 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.
Edge, SB, and Compton, CC. 2010. The American Joint Committee on Cancer: the 7th
edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17,
1471-1474. DOI: https://doi.org/10.1245/s10434-010-0985-4, PMID:20180029.
Geng, SQ, Alexandrou, AT, and Li, JJ. 2014. Breast cancer stem cells: Multiple capacities in
tumor metastasis. Cancer Lett 349, 1-7. DOI: https://doi.org/10.1016/j.canlet.2014.03.036,
PMID:24727284.
Gruber, R, Panayiotou, R, Nye, E, Spencer-Dene, B, Stamp, G, and Behrens, A. 2016. YAP1
and TAZ Control Pancreatic Cancer Initiation in Mice by Direct Up-regulation of JAK-
STAT3 Signaling. Gastroenterology 151, 526-539. DOI:
https://doi.org/10.1053/j.gastro.2016.05.006, PMID:27215660.
Hansen, CG, Moroishi, T, and Guan, KL. 2015. YAP and TAZ: a nexus for Hippo signaling
and beyond. Trends Cell Biol 25, 499-513. DOI: https://doi.org/10.1016/j.tcb.2015.05.002,
PMID:26045258.
Iliopoulos, D, Hirsch, HA, Wang, G, and Struhl, K. 2011. Inducible formation of breast
cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion.
Proc Natl Acad Sci U S A 108, 1397-1402. DOI: https://doi.org/10.1073/pnas.1018898108,
PMID:21220315.
Italiano, JE, Jr., and Shivdasani, RA. 2003. Megakaryocytes and beyond: the birth of
platelets. J Thromb Haemost 1, 1174-1182. DOI: https://doi.org/10.1046/j.1538-
7836.2003.00290.x, PMID:12871316.
Kaverina, N, Borovjagin, AV, Kadagidze, Z, Baryshnikov, A, Baryshnikova, M, Malin, D,
Ghosh, D, Shah, N, Welch, DR, Gabikian, P, Karseladze, A, Cobbs, C, and Ulasov, IV. 2017.
Astrocytes promote progression of breast cancer metastases to the brain via a KISS1-
mediated autophagy. Autophagy 13, 1905-1923. DOI:
https://doi.org/10.1080/15548627.2017.1360466, PMID:28981380.
24 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.
Kemeny, LV, and Fisher, DE. 2018. Targeting the (Un)differentiated State of Cancer. Cancer
Cell 33, 793-795. DOI: https://doi.org/10.1016/j.ccell.2018.04.007, PMID:29763619.
Khan, F, Amatya, B, Ng, L, Demetrios, M, Zhang, NY, and Turner-Stokes, L. 2012.
Multidisciplinary rehabilitation for follow-up of women treated for breast cancer. Cochrane
Database Syst Rev 12, CD009553. DOI: https://doi.org/10.1002/14651858.CD009553.pub2,
PMID:23235677.
Kilmister, EJ, Patel, J, van Schaijik, B, Bockett, N, Brasch, HD, Paterson, E, Sim, D, Davis,
PF, Roth, IM, Itinteang, T, and Tan, ST. 2020. Cancer Stem Cell Subpopulations Are Present
Within Metastatic Head and Neck Cutaneous Squamous Cell Carcinoma. Front Oncol 10,
1091. DOI: https://doi.org/10.3389/fonc.2020.01091, PMID:32850316.
Kim, T, Yang, SJ, Hwang, D, Song, J, Kim, M, Kyum Kim, S, Kang, K, Ahn, J, Lee, D, Kim,
MY, Kim, S, Seung Koo, J, Seok Koh, S, Kim, SY, and Lim, DS. 2015. A basal-like breast
cancer-specific role for SRF-IL6 in YAP-induced cancer stemness. Nat Commun 6, 10186.
DOI: https://doi.org/10.1038/ncomms10186, PMID:26671411.
Klein, CA. 2008. Cancer. The metastasis cascade. Science 321, 1785-1787. DOI:
https://doi.org/10.1126/science.1164853, PMID:18818347.
Langley, RR, and Fidler, IJ. 2007. Tumor cell-organ microenvironment interactions in the
pathogenesis of cancer metastasis. Endocr Rev 28, 297-321. DOI:
https://doi.org/10.1210/er.2006-0027, PMID:17409287.
Li, X, Wan, L, Shen, H, Geng, J, Nie, J, Wang, G, Jia, N, Dai, M, and Bai, X. 2012. Thyroid
transcription factor-1 amplification and expressions in lung adenocarcinoma tissues and
pleural effusions predict patient survival and prognosis. J Thorac Oncol 7, 76-84. DOI:
https://doi.org/10.1097/JTO.0b013e318232b98a, PMID:22011671.
Liu, H, Patel, MR, Prescher, JA, Patsialou, A, Qian, D, Lin, J, Wen, S, Chang, YF,
Bachmann, MH, Shimono, Y, Dalerba, P, Adorno, M, Lobo, N, Bueno, J, Dirbas, FM,
25 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.
Goswami, S, Somlo, G, Condeelis, J, Contag, CH, Gambhir, SS, et al. 2010. Cancer stem
cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse
models. Proc Natl Acad Sci U S A 107, 18115-18120. DOI:
https://doi.org/10.1073/pnas.1006732107, PMID:20921380.
Martin-Castillo, B, Oliveras-Ferraros, C, Vazquez-Martin, A, Cufi, S, Moreno, JM,
Corominas-Faja, B, Urruticoechea, A, Martin, AG, Lopez-Bonet, E, and Menendez, JA.
2013. Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell
dynamics to predict primary resistance to trastuzumab (Herceptin). Cell Cycle 12, 225-245.
DOI: https://doi.org/10.4161/cc.23274, PMID:23255137.
Meacham, CE, and Morrison, SJ. 2013. Tumour heterogeneity and cancer cell plasticity.
Nature 501, 328-337. DOI: https://doi.org/10.1038/nature12624, PMID:24048065.
Mehta, A, Kim, YJ, Robert, L, Tsoi, J, Comin-Anduix, B, Berent-Maoz, B, Cochran, AJ,
Economou, JS, Tumeh, PC, Puig-Saus, C, and Ribas, A. 2018. Immunotherapy Resistance by
Inflammation-Induced Dedifferentiation. Cancer Discov 8, 935-943. DOI:
https://doi.org/10.1158/2159-8290.CD-17-1178, PMID:29899062.
Murohashi, M, Hinohara, K, Kuroda, M, Isagawa, T, Tsuji, S, Kobayashi, S, Umezawa, K,
Tojo, A, Aburatani, H, and Gotoh, N. 2010. Gene set enrichment analysis provides insight
into novel signalling pathways in breast cancer stem cells. Br J Cancer 102, 206-212. DOI:
https://doi.org/10.1038/sj.bjc.6605468, PMID:19997106.
Mylona, E, Giannopoulou, I, Fasomytakis, E, Nomikos, A, Magkou, C, Bakarakos, P, and
Nakopoulou, L. 2008. The clinicopathologic and prognostic significance of CD44+/CD24(-
/low) and CD44-/CD24+ tumor cells in invasive breast carcinomas. Hum Pathol 39, 1096-
1102. DOI: https://doi.org/10.1016/j.humpath.2007.12.003, PMID:18495204.
26 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.
Najafi, M, Farhood, B, and Mortezaee, K. 2019. Cancer stem cells (CSCs) in cancer
progression and therapy. J Cell Physiol 234, 8381-8395. DOI:
https://doi.org/10.1002/jcp.27740, PMID:30417375.
Nishimura, R, Osako, T, Nishiyama, Y, Tashima, R, Nakano, M, Fujisue, M, Toyozumi, Y,
and Arima, N. 2013. Evaluation of factors related to late recurrence--later than 10 years after
the initial treatment--in primary breast cancer. Oncology 85, 100-110. DOI:
https://doi.org/10.1159/000353099, PMID:23867253.
O'Conor, CJ, Chen, T, Gonzalez, I, Cao, D, and Peng, Y. 2018. Cancer stem cells in triple-
negative breast cancer: a potential target and prognostic marker. Biomark Med 12, 813-820.
DOI: https://doi.org/10.2217/bmm-2017-0398, PMID:29902924.
Saini, KS, Taylor, C, Ramirez, AJ, Palmieri, C, Gunnarsson, U, Schmoll, HJ, Dolci, SM,
Ghenne, C, Metzger-Filho, O, Skrzypski, M, Paesmans, M, Ameye, L, Piccart-Gebhart, MJ,
and de Azambuja, E. 2012. Role of the multidisciplinary team in breast cancer management:
results from a large international survey involving 39 countries. Ann Oncol 23, 853-859.
DOI: https://doi.org/10.1093/annonc/mdr352, PMID:21821551.
Scott, J, Kuhn, P, and Anderson, AR. 2012. Unifying metastasis--integrating intravasation,
circulation and end-organ colonization. Nat Rev Cancer 12, 445-446. DOI:
https://doi.org/10.1038/nrc3287, PMID:22912952.
Sharma, P. 2018. Update on the Treatment of Early-Stage Triple-Negative Breast Cancer.
Curr Treat Options Oncol 19, 22. DOI: https://doi.org/10.1007/s11864-018-0539-8,
PMID:29656345.
Siegel, RL, Miller, KD, and Jemal, A. 2020. Cancer statistics, 2020. CA Cancer J Clin 70, 7-
30. DOI: https://doi.org/10.3322/caac.21590, PMID:31912902.
Stepanova, T, Slemmer, J, Hoogenraad, CC, Lansbergen, G, Dortland, B, De Zeeuw, CI,
Grosveld, F, van Cappellen, G, Akhmanova, A, and Galjart, N. 2003. Visualization of
27 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.
microtubule growth in cultured neurons via the use of EB3-GFP (end-binding protein 3-green
fluorescent protein). J Neurosci 23, 2655-2664. PMID:12684451.
Syn, N, Wang, L, Sethi, G, Thiery, JP, and Goh, BC. 2016. Exosome-Mediated Metastasis:
From Epithelial-Mesenchymal Transition to Escape from Immunosurveillance. Trends
Pharmacol Sci 37, 606-617. DOI: https://doi.org/10.1016/j.tips.2016.04.006,
PMID:27157716.
Tan, PH, Schnitt, SJ, van de Vijver, MJ, Ellis, IO, and Lakhani, SR. 2015. Papillary and
neuroendocrine breast lesions: the WHO stance. Histopathology 66, 761-770. DOI:
https://doi.org/10.1111/his.12463, PMID:24845113.
Thankamony, AP, Saxena, K, Murali, R, Jolly, MK, and Nair, R. 2020. Cancer Stem Cell
Plasticity - A Deadly Deal. Front Mol Biosci 7, 79. DOI:
https://doi.org/10.3389/fmolb.2020.00079, PMID:32426371.
Tzimas, C, Michailidou, G, Arsenakis, M, Kieff, E, Mosialos, G, and Hatzivassiliou, EG.
2006. Human ubiquitin specific protease 31 is a deubiquitinating enzyme implicated in
activation of nuclear factor-kappaB. Cell Signal 18, 83-92. DOI:
https://doi.org/10.1016/j.cellsig.2005.03.017, PMID:16214042.
Velasco-Velazquez, MA, Popov, VM, Lisanti, MP, and Pestell, RG. 2011. The role of breast
cancer stem cells in metastasis and therapeutic implications. Am J Pathol 179, 2-11. DOI:
https://doi.org/10.1016/j.ajpath.2011.03.005, PMID:21640330.
Wang, D, Lu, P, Zhang, H, Luo, M, Zhang, X, Wei, X, Gao, J, Zhao, Z, and Liu, C. 2014.
Oct-4 and Nanog promote the epithelial-mesenchymal transition of breast cancer stem cells
and are associated with poor prognosis in breast cancer patients. Oncotarget 5, 10803-10815.
DOI: https://doi.org/10.18632/oncotarget.2506, PMID:25301732.
28 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.
Wei, M, Zhu, Z, Wu, J, Wang, Y, Geng, J, and Qin, ZH. 2019. DRAM1 deficiency affects
the organization and function of the Golgi apparatus. Cell Signal 63, 109375. DOI:
https://doi.org/10.1016/j.cellsig.2019.109375, PMID:31356858.
Ye, S, Lawlor, MA, Rivera-Reyes, A, Egolf, S, Chor, S, Pak, K, Ciotti, GE, Lee, AC,
Marino, GE, Shah, J, Niedzwicki, D, Weber, K, Park, PMC, Alam, MZ, Grazioli, A, Haldar,
M, Xu, M, Perry, JA, Qi, J, and Eisinger-Mathason, TSK. 2018. YAP1-Mediated
Suppression of USP31 Enhances NFkappaB Activity to Promote Sarcomagenesis. Cancer
Res 78, 2705-2720. DOI: https://doi.org/10.1158/0008-5472.CAN-17-4052,
PMID:29490948.
Zoppino, FC, Militello, RD, Slavin, I, Alvarez, C, and Colombo, MI. 2010. Autophagosome
formation depends on the small GTPase Rab1 and functional ER exit sites. Traffic 11, 1246-
1261. DOI: https://doi.org/10.1111/j.1600-0854.2010.01086.x, PMID:20545908.
29 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.
Figure Legends
Figure 1.
Association of high CD44-/CD24- cell percentage with later tumor distant metastasis. (A)
Flow cytometry. Tissue samples from breast cancer patients with or without tumor metastasis
were processed and subjected to flow cytometric analysis of CD44-/CD24- cells. P values
were determined by Student’s t-test. (B) Receiver-operating characteristic curve. The data in
A were processed to generate the ROC curve to predict tumor metastasis events due to the
percentage of CD44-/CD24- cells. The area under the curve was 0.7055 (0.6468–0.7642;
P<0.0001), and the threshold from the ROC curve analysis was 19.5%. (C) Metastasis rates
in patients with different breast cancer molecular subtypes stratified by the percentage of
CD44-/CD24- cells. (D) Metastasis rates in patients with ≥2% CD44+/CD24- cells (n=105) vs.
C1 patients with <2% CD44+/CD24- cells and ≥19.5% CD44-/CD24- cells (n=69). (E)
Kaplan–Meier curves. The DFS of breast cancer patients was plotted for Kaplan–Meier
analysis and then subjected to the log rank test stratified by the percentage of CD44-/CD24-
cells vs. CD44+ cells. (F) Kaplan–Meier curves. The DFS of TNBC patients after
chemotherapy was plotted for Kaplan-Meier analysis and then subjected to the log rank test
stratified by ≥19.5% CD44-/CD24- cells (n=52) vs. <19.5% CD44-/CD24- cells (n=80). (G)
Kaplan–Meier curves. The DFS of luminal breast cancer patients after endocrine therapy was
plotted for Kaplan–Meier analysis and then subjected to the log rank test stratified by ≥19.5%
CD44-/CD24- cells (n=24) vs. <19.5% CD44-/CD24- cells (n=23).
29 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.
Figure 2.
Ability of CD44-/CD24- tumor cell percentage to predict the success of adjuvant TNBC
treatment. (A) Postoperative metastasis rate in the test group of patients with different breast
cancer molecular subtypes stratified by the percentage of CD44-/CD24- cells. (B) Metastasis
rate in all breast cancer patients (n=211) vs. patients with the ≥2% CD44+/CD24- cells (n=68)
vs. C1 patients with the <2% CD44+/CD24- and ≥19.5% CD44-/CD24- cells (n=153). (C and
D) Kaplan–Meier curves. The DFS (C) and OS (D) of all patients in the testing group
stratified by ≥19.5% CD44-/CD24- (n=100) vs. <19.5% CD44-/CD24- tumor cells (n=121).
(E) Kaplan–Meier curves. The DFS in the test group of TNBC patients after chemotherapy
stratified by ≥19.5% CD44-/CD24- (n=24) vs. <19.5% CD44-/CD24- tumor cells (n=35). (F)
Kaplan–Meier curves. The DFS in the test group of luminal breast cancer patients after
endocrine therapy stratified by ≥19.5% CD44-/CD24- (n=22) vs. <19.5% CD44-/CD24- tumor
cells (n=19). P-values were obtained by log-rank test.
30 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.
Figure 3.
Spontaneous conversion of CD44-/CD24- TNBC cells into CD44+/CD24- CSCs. (A)
Illustration of CD44-/CD24- cell generation and sorting. (B) Flow cytometry. MDA-MB-231
cells were sorted with flow cytometry and then cultured in stem cell (SC) or L15 medium for
7 days. Then, the percentage of CD44+/CD24- CSCs in CD44-/CD24- MDA-MB-231 cells
was analyzed by flow cytometry. (C) Flow cytometry. CD44-/CD24- MDA-MB-231 cells
were further sorted for CD44+/CD24- CSCs by flow cytometry on days 7 and 21.
31 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.
Figure 4.
Similar properties of newly converted CSCs from CD44-/CD24- TNBC cells to those of
parental TNBC cells in vitro. (A) Morphology of CD44+/CD24- CSCs derived from parental
MDA-MB-231 (WT) and CD44-/CD24- MDA-MB-231 cells. CD44-/CD24- MDA-MB-231
cells were sorted by flow cytometry for CD44-/CD24- cells, plated in cell culture dishes, and
cultured for 7 days. Mammospheres were then photographed, and their number and size
quantified. (B) Cell viability CCK-8 assay. The sorted CD44+/CD24- CSCs (WT) and CD44-
/CD24- MDA-MB-231 cells from A were subjected to cell viability CCK-8 assay after
culture for 24, 48, and 72 h. (C) Flow cytometry. The duplicated CSCs from WT and CD44-
/CD24- MDA-MB-231 cells were cultured in stem cell (SC) medium for 7 days and then
sorted by flow cytometry. (D) Western blot. The sorted CD44+/CD24- CSCs (WT) and CD44-
/CD24- MDA-MB-231 cells were then subjected to western blot analysis of the expression of
stemness biomarkers, such as OCT4, SOX2, NANOG, Nestin, and ABCB1. (E) Flow
cytometry. CD44+/CD24- CSCs from parental MDA-MB-231 and CD44-/CD24- cells
converted MDA-MB-231 cells were cultured in stem cell (SC) medium for 7 days and then
subjected to flow cytometry.
32 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.
Figure 5.
Similar properties of newly converted CSCs from CD44-/CD24- TNBC cells to those of
parental TNBC cells in vivo. (A) Tumor cell xenografts. Equal numbers of CSCs from
CD44+/CD24- (WT) and CD44-/CD24- MDA-MB-231 cells were injected into BALB/c nude
mice and grown for 21 days. After that, the mice were sacrificed, and the tumor xenografts
were harvested, photographed (n=5-8 per group), and weighed. Tumor size also was
measured. The data in the graphs for tumor weight and size are mean ± standard deviation
(SD) for each group from three independent experiments. **P<0.01 using Student’s t-test.
(B) Flow cytometry. The percentages of CSCs in different subtypes of MDA-MB-231 cells
from individual xenografted tumors in A were analyzed by flow cytometry. (C) In vivo tumor
cell lung metastasis. Equal numbers of CSCs from CD44+/CD24- and CD44-/CD24-
converted MDA-MB-231 cells were injected into the tail vein of NOD/SCID mice and grown
for 21 days to assess their lung metastasis. After that, the mice were sacrificed, and the tumor
cell lung metastasis was resected. The tissue processed was for hematoxylin and eosin (H&E)
staining and photographed (n=5–8 per group), and tumor weight and size were measured in
each group.
33 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.
Figure 6.
RHBDL2 involvement in the regulation of spontaneous conversion of CD44-/CD24- MDA-
MB-231 cells into CD44+/CD24-CSCs as analyzed by single-cell RNA-seq. (A) Morphology.
The CD44-/CD24- MDA-MB-231 cells were grown and transfected with OCT4-EGFP
plasmid to illustrate the stem-like cells, cultured for 24 h, 72 h, and 120 h, and photographed.
(B) RNA-seq analysis. The CD44-/CD24- MDA-MB-231 cells were grown and sorted by
flow cytometry, and the resultant cells were grown and transfected with pGL3-OCT4-EGFP.
Single cells were then captured at 24, 72, and 120 h, isolated, and subjected to RNA-seq
analysis of DEGs. The major DEGs are shown in a heat map. (C) Kaplan–Meier plot for
survival analysis. We generated Kaplan-Meier curves and applied the log-rank test to analyze
associations of some selected DEGs with breast cancer prognosis using The Cancer Genome
Atlas (TCGA) data according to the data in B. (D) qRT-PCR. The expression levels of
different mRNAs selected from B were analyzed using qRT-PCR in CD44+/CD24-, CD44-
/CD24-, and CD44+/CD24- cells derived from CD44-/CD24- cells after 7 days in culture.
34 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.
Figure 7.
Mitigation of CD44-/CD24- cell dedifferentiation into CSCs with RHBDL2 silencing in
TNBC cells after inhibition of YAP1/NF-κB signaling. (A) YAP1 and phosphorylated YAP1
levels in MDA-MB-231 and RHBDL2-silenced MDA-MB-231 cells determined by western
blot analysis. (B) USP31 and phosphorylated NF-κB levels in CD44-/CD24- and RHBDL2-
silenced CD44-/CD24- cells determined by western blot analysis. (C) Cytoplasmic and
nuclear YAP1 protein levels in MDA-MB-231 and RHBDL2-silenced MDA-MB-231 cells
determined by western blot analysis. (D) Mammosphere formation by CSCs. MDA-MB-231
CD44-/CD24- cells were grown and transfected with the negative control or RHBDL2-
specific siRNA. After culture in SC medium for 7 days, mammospheres were randomly
selected and photographed at 400×. The graphs show quantified data for mammospheres
visible in five or more images from each of three wells. (E, F, and G) Illustration of the
possible mechanisms underlying the enhanced conversion of CD44-/CD24- cells into
CD44+/CD24- CSCs among RHBDL2-silenced TNBC cells.
35 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.
Supplementary information
Figure S1. Immunofluorescent staining of CD44+/CD24- and CD44-/CD24- cancer cells in
human breast cancer specimens. (A) Representative fluorescent images of breast cancer cells
stained by anti-CD24 and anti-CD44 antibodies. Scale bar, 20 μm; high CD44+/CD24- cells
(≥2%) and low ones (<2%). (B) Representative fluorescent images of cancer cells stained by
anti-CD24 and anti-CD44 antibodies. Scale bar, 20 μm; high CD44-/CD24- cells (≥19.5%)
and low ones (<19.5%).
31 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.
Figure S2. Diagnostic and prognostic value of stratification of metastatic tumors by the
percentage of CD44-/CD24- cancer cells. (A) Flow cytometric analysis of the percentages of
CD44+/CD24+, CD44-/CD24-, CD44-/CD24+, and CD44+/CD24- cells in breast cancer tissue
specimens (n=355). ****P<0.0001 comparing CD44+/CD24- cells and CD44-/CD24- cells
using Student’s t-test. (B) Tumor metastasis in postoperative breast cancer patients after 4
years stratified by the different breast cancer molecular subtypes and the percentage of CD44-
/CD24- cells. (C) Tumor metastasis of breast cancer patients stratified by the percentage of
CD44+/CD24- cells (≥2%; n=105 vs. <2%; n=250). (D) Kaplan–Meier curves. The DFS of
patients with luminal breast cancer (≥2% CD44+/CD24- cells; n=47 vs. <2%; n = 112), HER-
2-positive breast cancer (≥2% CD44+/CD24- cells; n=14 vs. <2% one; n=25), and TNBC
breast cancer (≥2% CD44+/CD24- cells; n=44 vs. <2%; n=113).
32 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.
Figure S3. Kaplan–Meier and the log-rank test analysis of disease-free survival (DFS) in
breast cancer patients stratified by percentage of CD44-/CD24- cells. (A) Luminal (≥19.5%
CD44-/CD24- cells; n=71 vs. <19.5%; n=88), HER-2-positive (≥19.5% CD44-/CD24- cells;
n=17 vs. <19.5%; n=22), and TNBC breast cancer (≥19.5% CD44-/CD24- cells; n=58 vs.
<19.5%; n=99). (B) Stratified by chemotherapy (≥19.5% CD44-/CD24- cells; n=118 vs.
<19.5%; n=161). (C) Stratified by the low CSC level among tumor cells after chemotherapy
(≥19.5% CD44-/CD24- cells; n=54 vs. <19.5%; n=138). (D) Stratified by TNBC after
chemotherapy (≥19.5% CD44-/CD24- cells; n=21 vs. <19.5%; n=70).
33 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.
Figure S4. Kaplan–Meier and the log-rank test analysis of DFS and OS in the test group of
patients stratified by percentage of CD44-/CD24- cells. (A) DFS of stratified luminal cases
(≥19.5% CD44-/CD24- cells; n=44 vs. <19.5%; n=45), HER-2-positive cases (≥19.5% CD44-
/CD24- cells; n=31 vs. <19.5%; n=37), and TNBC cases (≥19.5% CD44-/CD24- cells; n=25
vs. <19.5% ones; n=39). (B) OS of stratified luminal cases (≥19.5% CD44-/CD24- cells;
n=44 vs. <19.5%; n=45), HER-2-positive cases (≥19.5% CD44-/CD24- cells; n=31 vs.
<19.5% ones; n=37), and TNBC cases (≥19.5% CD44-/CD24- cells; n=25 vs. <19.5%; n=39).
(C) DFS stratified by low CSC level after chemotherapy (≥19.5% CD44-/CD24- cells; n=47
vs. <19.5%; n=94). (D) DFS and OS stratified by >19.5% CD44-/CD24- cells (n=51) vs. <
19.5% ones (n=181) in patients with <2% CD44+/CD24- cells.
34 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.
Figure S5. Representative images of flow cytometric data on the conversion of CD44-/CD24-
TNBC cells into CD44+/CD24- CSCs in vitro. After sorting the CD44-/CD24- cells by flow
cytometry and culturing them in SC or L15 medium for 7 days, the percentage of
CD44+/CD24- CSCs in CD44-/CD24- MDA-MB-468 cells was further analyzed by flow
cytometry.
35 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.
Figure S6. Bioinformatic analysis of DEGs between 24-h dedifferentiated single cells and
CD44-/CD24- MDA-MB-231 cells. (A) The most up- and down-regulated DEPs between 24-
and 72-h samples identified by stable-isotope labeling by amino acids in cell culture assay
(SILAC). (B) GO term for the DEGs. (C) KEGG analysis of the DEGs.
36 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.
Table S1. Clinicopathological characteristics of patients
Variables Training set Testing set n (%) n (%) Number of patients 355 221 Median age at 51 51 diagnosis (yrs.) Molecular subtype Luminal 159 (44.79) 89 (40.27)
HER-2 39 (10.99) 68 (30.77)
TNBC 157 (44.22) 64 (28.96) N stage
N0 240 (67.61) 123 (55.66) N1 69 (19.44) 62 (28.05)
N2 25 (7.04) 17 (7.69)
N3 21 (5.91) 19 (8.60) T stage T1 196 (55.21) 63 (28.51)
T2 156 (43.94) 147 (66.51)
T3 3 (0.85) 11 (4.98) Clinical stage
I 110 (30.99) 31 (14.03) II 198 (55.77) 156 (70.59)
III 47 (13.24) 34 (15.38) Lymph node 115 (32.39) 98 (44.34) involvement Distant metastases 105 (29.58) 52 (23.53) Bone metastases 19 (5.35) 22 (9.95) Follow-up in months 96 (5 - 96) 78 (9 - 96) Death 37 (10.42) 54 (24.43)
7 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.
Table S2. Univariate and multivariate Cox regression analyses of clinicopathological factors as predictors of DFS
Variables Univariate analysis Multivariate analysis HR (95%CI) P-value HR (95%CI) P-value Percentage of CD44-/CD24- cells 4.153 (2.727– <0.0001 2.621 (1.631–4.214) <0.0001
>19.5% versus <19.5% 6.326) Frequency of CD44+/CD24- cells 5.259 (3.548– <0.0001 3.712 (2.384–5.780) <0.0001
≥2% versus <2% 7.794)
Lymph node involvement
Yes versus No 1.672 (1.133– 0.0096 0.322 (0.053–1.943) 0.21 2.468) N stage 0.0023 0.027
N1 versus N0 1.510 (0.948– 0.083 3.693 (0.589– 0.16 2.405) 23.141) N2 versus N0 1.310 (0.599– 0.49 2.437 (0.292– 0.41 2.864) 20.316)
N3 versus N0 3.776 (2.031– <0.0001 10.166 (1.066– 0.043 7.019) 96.998) Molecular subtype 0.025 0.020 HER-2 versus Luminal 1.296 (0.658– 0.45 2.553)
TNBC versus Luminal 1.762 (1.160– 0.0079 4.190 (1.244–4.106) 0.020 2.677) Clinical stage 0.0094 0.90 II vs. I 1.414 (0.887– 0.145 1.065 (0.544–2.085) 0.85 2.255) III vs. I 2.581 (1.433– 0.0016 1.358 (0.358–5.157) 0.6526 4.649) Ki67 index 0.020 0.16
14%-30% versus 0-14% 1.765 (0.813– 0.15 1.760 (0.769–4.029) 0.18
8 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.
3.832)
>30% versus 0-14% 1.904 (1.201– 0.0061 1.520 (0.911–2.536) 0.10 3.017) PR status
Positive versus Negative 0.595 (0.395– 0.012 0.801 (0.372–1.723) 0.56 0.896)
9 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.07.414599; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.
Table S3. Primary antibodies used in western blotting Protein Catalog number Manufacturer GAPDH 10494-1-AP Proteintech (Rosemont, IL, USA) OCT4 11263-1-AP Proteintech SOX2 11064-1-AP Proteintech ABCB1 22336-1-AP Proteintech YAP 13584-1-AP Proteintech Tubulin-β 10094-1-AP Proteintech Alpha-tubulin 11224-1-AP Proteintech Phospho-YAP KA1392C Immunoway (Plano, TX, USA) NF-κB YM3111 Immunoway Phospho-NF-κB YP0188 Immunoway USP31 ab240543 Abcam (Cambridge, MA, USA) NANOG ab80892 Abcam Nestin ab22035 Abcam Lamin B1 12987-1-AP Proteintech
10